The Concurrent Use of Aromatase Inhibitors and Radiotherapy Induces Echocardiographic Changes in Patients with Breast Cancer

被引:0
|
作者
Skytta, Tanja [1 ,3 ]
Tuohinen, Suvi [2 ,3 ]
Virtanen, Vesa [2 ,3 ]
Raatikainen, Pekka [2 ,3 ]
Kellokumpu-Lehtinen, Pirkko-Liisa [1 ,3 ]
机构
[1] Univ Tampere, Dept Oncol, FIN-33101 Tampere, Finland
[2] Univ Tampere, Tampere Univ Hosp, Heart Ctr, FIN-33101 Tampere, Finland
[3] Univ Tampere, Sch Med, FIN-33101 Tampere, Finland
关键词
Breast cancer; radiotherapy; cardiotoxicity; aromatase inhinitors; POSTMENOPAUSAL WOMEN; THERAPY; STANDARDIZATION; MECHANISMS; EXPRESSION; LETROZOLE; TAMOXIFEN; ESTROGEN; DISEASE;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: Adjuvant radiotherapy (RT) for left-sided breast cancer has a negative impact on cardiac health. The concurrent use of aromatase inhibitors (AIs) during RT was found to increase the anticancer efficacy of radiation in preclinical models. We evaluated whether the acute effects of RT on cardiac functions are augmented by the concurrent use of AIs. Patients and Methods: Sixty patients with early-stage left-sided breast cancer underwent a 2D echocardiography, electrocardiogram and cardiac biomarker measurements before and after adjuvant breast RT. Data were analyzed in two groups according to AI use. Results: We observed a significant (p<0.05) decrease in right ventricular systolic function during RT in tricuspid annular plane systolic excursion (TAPSE). TAPSE decreased by 3.0 mm [95% confidence interval (CI)=1.9-4.1 mm] in the AI group and 1.4 mm (95% CI=0.3-2.4 mm) in the non-AI group. In addition, left ventricular diastolic function decreased among patients using AI, as the mitral inflow E-wave decreased 5.8 cm/s (95% CI=1.8-9.7 ends) (p=0.006). Conclusion: The concurrent use of AI during RT for left-sided breast cancer led to a more pronounced change on right ventricular systolic function and left ventricular diastolic functions compared to RT alone.
引用
收藏
页码:1559 / 1566
页数:8
相关论文
共 50 条
  • [41] Body mass index and aromatase inhibitors: a step forward in individualizing therapy for breast cancer patients?
    Slowik, Agnieszka
    Fraczek, Paulina A.
    Krzemieniecki, Krzysztof
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (07) : 759 - 766
  • [42] Prevalence of depressive syndrome in patients with breast cancer treated with or without aromatase inhibitors
    Couillet, A.
    Tredan, O.
    Oussaid, N.
    Saltel, P.
    ONCOLOGIE, 2015, 17 (11-12) : 587 - 594
  • [43] Vascular function in breast cancer survivors on aromatase inhibitors: a pilot study
    Blaes, Anne
    Beckwith, Heather
    Florea, Natalia
    Hebbel, Robert
    Solovey, Anna
    Potter, David
    Yee, Douglas
    Vogel, Rachel
    Luepker, Russell
    Duprez, Daniel
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 166 (02) : 541 - 547
  • [45] Aromatase inhibitors for the treatment of breast cancer: An overview (2019-2023)
    Bhatia, Neha
    Thareja, Suresh
    BIOORGANIC CHEMISTRY, 2024, 151
  • [46] Current role and safety profile of aromatase inhibitors in early breast cancer
    Tomao, Federica
    Spinelli, GianPaolo
    Vici, Patrizia
    Pisanelli, Giovanni Codacci
    Cascialli, GianLuca
    Frati, Luigi
    Panici, PierLuigi Benedetti
    Tomao, Silverio
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (08) : 1253 - 1263
  • [47] Radiotherapy concurrent versus sequential with endocrine therapy in breast cancer: A meta-analysis
    Li, Yun-Fen
    Chang, Li
    Li, Wen-Hui
    Xiao, Min-Yang
    Wang, Yong
    He, Wen-Jie
    Xia, Yao-Xiong
    Wang, Li
    Chen, Yan
    BREAST, 2016, 27 : 93 - 98
  • [48] Skeletal adverse effects with aromatase inhibitors in early breast cancer: evidence to date and clinical guidance
    Servitja, Sonia
    Martos, Tamara
    Rodriguez Sanz, Maria
    Garcia-Giralt, Natalia
    Prieto-Alhambra, Daniel
    Garrigos, Laia
    Nogues, Xavier
    Tusquets, Ignasi
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2015, 7 (05) : 291 - 296
  • [49] Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer
    Arnedos, M.
    Drury, S.
    Afentakis, M.
    A'Hern, R.
    Hills, M.
    Salter, J.
    Smith, I. E.
    Reis-Filho, J. S.
    Dowsett, M.
    ANNALS OF ONCOLOGY, 2014, 25 (03) : 605 - 610
  • [50] Aromatase Inhibitors as Solely Treatment in Postmenopausal Breast Cancer Patients
    Hille, Ursula
    Soergel, Philipp
    Laenger, Florian
    Schippert, Cordula
    Makowski, Lars
    Hillemanns, Peter
    BREAST JOURNAL, 2012, 18 (02) : 145 - 150